Latest Conference Articles

New research presented at ARVO 2023 suggests intravitreal brolucizumab led to the resolution of IRF and SRF in a significant number of patients with nAMD previously unresponsive to anti-VEGF therapy.

In an interview at ARVO 2023, Danzig discusses the post-hoc analysis from the GATHER trials, showing that a reduced rate of vision loss in patients receiving avacincaptad pegol was correlated with reduced GA growth.

At ARVO 2023, Caroline Baumal, MD, chief medical officer of Apellis Pharmaceuticals, discussed new phase 3 functional analyses of pegcetacoplan injection, the future of the GA treatment landscape, and the next unmet need in ophthalmology.

Phase 3 results presented at ARVO 2023 suggest a switch from aflibercept to SB15 led to no treatment-emergent issues such as loss of efficacy, increased adverse events, or increased immunogenicity.

An analysis of the STATUS program suggests the percentage of patients that received an annual eye exam increased from 65.2% to 72.8% in the clinics utilizing the IDx-DR system.

An analysis of the AlzEye study presented at ARVO 2023 suggests a deep-learning model showed promise in predicting three-year incident MACE using OCT.

As part of our ARVO 2023 coverage, Dr. Sheth sat down with Pravin Dugel, MD, President of Iveric Bio to discuss avacincaptad pegol for geographic atrophy and a look back at Dr. Dugel's career and his transition into industry.

Siperstein highlighted some more major takeaways from her conference presentation, including facts about how to determine which patients are good candidates for microneedling.

In this interview, Siperstein explained some of the biggest takeaways from her conference presentation on advances in microneedling techniques, including radiofrequency specifically.

“These findings are exciting for us, and our overarching goal is to develop microbial biotherapeutics to treat food allergies," Mustafa Özçam says in an interview with HCPLive.

Symptoms including vestibular rashes and COVID toes have become less synonymous with SARS-CoV-2 infection. Why is that?

Speaking about one of his conference presentations, Chovatiya highlights the biggest takeaways regarding JAK inhibitors for alopecia areata, vitiligo, eczema, psoriasis, and more.

In another interview segment, Cohen described several other major takeaways from his conference presentation on psoriasis, comorbidities, and therapies.

In a conference interview, Cohen delved into the major takeaways covered in his presentation on the latest information related to psoriasis and its therapy.

In recently-presented data, ivarmacitinib was found to have decreased severity of moderate-to-severe eczema compared to placebo.

As the pandemic passes its third year, one dermatologist foresees their field's own pursuit of specialty-specific vaccination guidelines.

New late-breaking data showed that oral roflumilast treatment was both safe and efficacious against psoriasis, making it a potentially less expensive and convenient treatment alternative.

New late-breaking data supported prior results indicating that all primary and secondary endpoints were reached for the IL-4Rα antibody known as CBP-201 for atopic dermatitis patients.

New phase 2b data show the oral PDE4 inhibitor could reduce psoriasis area severity by more than 60% in 16 weeks.

New late-breaking data showed positive results for bimekizumab treatment of hidradenitis suppurativa, with higher response rates and a strong safety profile.

In research drawn from his conference presentation, Lim discussed the unique photoprotection needs of skin of color as well as some of the challenges faced by patients in this population.

A small molecule IL-17A inhibitor, izokibep has additionally shown efficacy in treating psoriatic arthritis—and will now be reviewed in a phase 3 HS trial.

Pediatric dermatologist Mercedes Gonzalez, MD, discusses the new phase 3 B-SIMPLE data supporting berdazimer gel as the first potential molluscum treatment.

Kwatra spoke about his team’s research into nemolizumab for prurigo nodularis in the OLYMPIA 2 trial, including the data and its implications for the future.

New data indicates that an oral TYK2 inhibitor known as NDI-034858 showed strong results for psoriasis patients in a recent phase 2b trial.

New data has indicated that patients with psoriasis who were not responding to ixekizumab or secukinumab responded well to risankizumab, an interleukin-23 inhibitor.

Late-breaking data on roflumilast cream for eczema patients in two phase 3 trials titled INTEGUMENT-1 and INTEGUMENT-2 showed strong results for the drug.

In a new interview, Eichenfield discussed the background of his presentation on late-breaking data from the INTEGUMENT-1 and INTEGUMENT-2 trials on roflumilast for atopic dermatitis.